Author

Quinn T. Cowan

Gladstone InstitutesORCID 0000-0002-8697-8178Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetic & Genomic Medicine· 1 Genetics· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:CRISPR screen· 1

Frequent Co-Authors

Bruce R. ConkliniD· 2 shared Grace D. RameyiD· 2 shared Hannah L. Watry· 2 shared John A. CapraiD· 2 shared Luke M. JudgeiD· 2 shared Abin AbrahamiD· 1 shared Akshita Saxena· 1 shared Bazilco M.J. Simon· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Bruce R. ConklinORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Leveraging human genetic variation to therapeutically target hundreds of genes with dominant & dispensable disease alleles

Grace D. Ramey, Quinn T. Cowan, Akshita Saxena, Bria L Macklin, Hannah L. Watry, Xiaoyue Mei, Philip H. Dierks, Luke M. Judge, Bruce R. Conklin, John A. Capra

This paper identifies therapeutic opportunities for over 500 genes with dominant and dispensable disease alleles by enabling mutation-agnostic gene therapy through allele-specific targeting.

medRxiv · Mar 27, 2026 · PreprintGenetic & Genomic Medicine

Haplotype editing with CRISPR/Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL

Poorvi H. Dua, Bazilco M.J. Simon, Chiara B.E. Marley, Carissa M. Feliciano, Hannah L. Watry, Quinn T. Cowan, Dylan Steury, Abin Abraham, Erin N. Gilbertson, Grace D. Ramey, John A. Capra, Bruce R. Conklin, Luke M. Judge

This paper demonstrates haplotype editing with CRISPR/Cas9 to target NEFL missense mutations in iPSC-derived motor neurons, showing therapeutic potential and challenges in disrupting mutant allele expression.

Molecular Therapy · Nov 20, 2025Peer-reviewedGenetics